FilingsTodayEagle Veterinary Technology
At a glance
Eagle Veterinary Technology filed 16 disclosures in the last 12 months, including 1 buyback and 1 issuance. The most recent key filing was on Dec 15.
Revenue for 2025 was ₩43.3B, up 3.9% on 2024. Operating margin was 9.8% against 8.3% a year earlier. Debt was 23% of equity at year end. The latest interim report (2026 H1) shows revenue of ₩23.2B and operating profit of ₩3.1B.
The 2025 annual report lists 110 employees with an average tenure of 10.2 years and average pay of ₩48.3M, #1526 of 1,829 listed companies by average pay. Its 4 directors and auditors were paid ₩69.3M each on average. It paid ₩80 per common share in cash dividends, against ₩60 a year earlier (+33.3%). 강승조(*1) and related parties held 38.40% at year end.
From the 2025 annual report
Staff: 110 (69 men, 41 women), of whom 7 on fixed-term contracts. Total pay for the year: ₩5.3B. Directors and auditors: 4, paid ₩277M in total.
Dividends (common shares)
| Fiscal year | 2025 | 2024 | 2023 |
|---|---|---|---|
| Cash dividend per share | ₩80 | ₩60 | ₩40 |
| Payout ratio | 24.9% | 19.9% | 16.5% |
| Yield (as filed) | 1.80% | 1.20% | 0.70% |
| Total cash dividends | ₩982M | ₩736M | ₩491M |
Largest shareholder
강승조(*1) holds 14.79%; with 3 related parties the group holds 38.40% of common shares at year end.
Auditor: 대주회계법인 · opinion: Unqualified.
Source: 2025 annual business report (DART). How figures are combined
Financial summary
Key filings
Other filings
Links open the original filing on DART, in Korean.